晚期非小细胞肺癌吉非替尼治疗3年生存因素分析  

Analysis of the factors affecting the survival of gefitinib-treated advanced NSCLC patients

作　　者：缪若羽[1] 李龙芸[1] 王树兰[1] 王孟昭[1] 杨琦莉[1] 钟巍[1] 张晓彤[1] 李俊荣[1] 张力[1] 

机构地区：[1]中国医学科学院北京协和医学院北京协和医院呼吸内科,北京100730

出　　处：《癌症进展》2009年第2期179-183,共5页Oncology Progress

摘　　要：目的探讨表皮生长因子受体酪氨酸激酶抑制剂吉非替尼治疗晚期非小细胞肺癌(NSCLC)长期生存的影响因素。方法分析2002年12月～2006年4月北京协和医院204例晚期NSCLC患者经吉非替尼250mg/日口服治疗的3年生存情况。应用x^2检验进行统计分析。结果吉非替尼长期生存优于化疗,3年生存率16.2%。吸烟史(P= 0.043)、治疗疗效(P=0.002)和病理类型(P=0.011)是与吉非替尼治疗生存时间密切相关的因素,而性别(P=0.762)、年龄(P=0.053)、ECOG评分(P=0.380)、既往治疗方法(P=0.222)及临床分期(P=0.135)则与之无显著关系。结论吉非替尼是1种有效的治疗NSCLC的靶向药物,可以改善NSCLC患者的生存时间。根据患者具体情况选择合适肺癌患者并进行吉非替尼治疗可望使肺癌治疗更为个体化,具有更好的临床应用前景。Objective To investigate the factors that influence the long-term survival of patients with advanced non- small cell lung cancer （NSCLC） who were treated with epidermal growth factor receptor （EGFR） -tyrosine kinase inhibitor gefitinib （Iressa）. Methods From December 2002 to April 2006, 204 patients with advanced NSCLC were enrolled for treatment with gefitinib 250mg once daily in Peking Union Medical College Hospital. Clinical data was analyzed by Pearson＇s Chi-square test. Results The long-term survival of Gefitinib-treated patients had a 3-year survival rate of 16.2%, which was correlated with smoking history （ P = 0. 043 ）, the curative effect of gefitinib therapy （ P = 0. 002 ）, and pathological type （P = 0.011 ）. It was not correlated with gender （P = 0. 762）, age （P = 0. 053 ）, ECOG score （ P = 0. 380） former therapeutic history （ P = 0. 222）, and clinical stage （ P = 0. 135 ）. Conclusion Gefitinib offers a new treatment option for advanced NSCLC

关 键 词：吉非替尼 非小细胞肺癌 靶向治疗 

分 类 号：R734.2[医药卫生—肿瘤] R730.54[医药卫生—临床医学]